AUS
NZ
UK
CA
USA
IND
Health Canada has authorized the Pfizer-BioNTech COVID-19 vaccine for minors between the ages of 12 and 16. Earlier, the healthcare regulator had approved the Pfizer shot only for people above the age of 16.
This decision came after the duo vaccine makers held a trial with over 2,200 kids in that age group in the US and noted no cases of COVID-19 among inoculated kids.
Health Canada's head medical counselor Dr Supriya Sharma said the trial results have shown that this vaccine shot is safer and successful in that age group.
Meanwhile, stocks of BioNTech SE (BNTX:US, NASDAQ:BNTX) jumped over 10 per cent on the back of Health Canada’s approval. Its partner Pfizer Inc’s (PFE:US, NYSE:PFE) stock increased by more than two per cent (as of 10:50AM EST).
Let us glance at these healthcare stocks’ price performances.
BioNTech SE (BNTX:US, NASDAQ:BNTX)
German biotechnology firm BioNTech SE’s share price has rocketed 138.4 per cent this year. The COVID vaccine maker’s stock zoomed almost 289 per cent in the past year and topped the S&P 500 Biotechnology Sub Industry in comparison.
The 46.7-billion market cap company’s shares have been actively trading recently, with a 10-day average volume of over four million. Its stock price was US$ 194.2 apiece on Wednesday morning (10:50AM EST).
The stock touched its all-time high of US$ 213.15 apiece on May 4, led by the successful submission for marketing license for its COVID-19 vaccine with the European Union.
©Kalkine Group 2021
Pfizer Inc (PFE:US, NYSE:PFE)
One of the world's largest pharma companies, Pfizer Inc commercializes drug sales worth nearly US$ 50 billion on a yearly basis. The American drug maker’s share price has gained 11 per cent this year and outperformed the benchmark index in comparison.
Its one-year growth is almost 12 per cent. Its current share price is US$ 40.81 apiece, which is approaching its 52-week high of US$ 43.07 (December 09, 2020).
On April 28, the company announced that it purchased Amplyx Pharmaceuticals Inc, which is specialized in developing therapies for weaker immune systems.
